Avastin/Lucentis Update 39: And the Controversy Continues

This article was published in yesterday’s Wall Street Journal. It again illustrates how Medicare operates with one hand tied behind its back.


WSJ, June 17, 2010

By Alicia Mundy

Medicare could save more than $500 million annually by using a cheaper Genentech drug to save vision, according to a draft study by federal officials and a University of Miami eye doctor.

The study shows that the cheaper drug, Avastin, is already used in about 65% of Medicare patients with wet age-related macular degeneration and accounts for nearly 60% of their eye injections, compared with (Read more...)

Full Story →